|
Using a specific anti-vascular endothelial growth factor (VEGF) drug in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) can result in a ≥2-step improvement in diabetic retinopathy severity scores (DRSS) in almost 60% of those treated, according to results of the PANORAMA study.
Read more
|